Knowing more about cancer can help both patient and family members cope more effectively. Oncology clinical research trials are administered through the Parkview Research Center. Current studies include treatments for brain, breast, lung, bone, bladder, prostate and esophageal cancers.
For further information about the current Parkview studies, visit Parkview Research Center. A physician’s referral is required for participation in Parkview clinical trials.
The trials underway include:
- International randomized study to compare CyberKnife® stereotactic radiotherapy with surgical re-section in Stage I non-small cell lung cancer
- Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving Cisplatin and Etoposide
- Phase III randomized trial of the role of whole-brain radiation therapy in addition to radiosurgery in patients with one to three cerebral metastases
- A Phase III clinical trial comparing Trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER-2 positive ductal carcinoma in situ re-sected by lumpectomy
- A Phase III trial comparing whole-brain radiation and stereotactic radiosurgery alone versus with Temozolomide or Erlotinib in patients with non-small cell lung cancer and one to three brain metastases
- A randomized Phase III study of conventional whole-breast irradiation (WBI) versus partial breast irradiation (PBI) for women with Stage 0, I or II breast cancer
- A Phase III international randomized trial of single versus multiple fractions for re-irradiation of painful bone metastases
- A Phase III trial evaluating the addition of Cetuximab to Paclitaxel, Cisplatin, and radiation for patients with esophageal cancer who are treated without surgery
- A Phase III protocol of androgen suppression (AS) and 3-D CRT/IMRT versus AS and 3-D CRT/IMRT followed by chemotherapy with Docetaxel and Prednisone for localized, high-risk prostate cancer
- A Phase I/II trial of a combination of Paclitaxel and Trastuzumab with daily irradiation or Paclitaxel alone with daily irradiation following transurethral surgery for non-cystectomy candidates with muscle-invasive bladder cancer
- A Phase III trial of short-term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy